PDK-1/AKT signaling inhibitors
View Patent ↗A new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of formula I: wherein X is selected from the group consisting of alkyl and haloalkyl; Ar is an aryl radical selected from the group consisting of phenyl, biphenyl, naphthyl, anthryl, phenanthryl, and fluorenyl; and wherein Ar is optionally substituted with one or more radicals selected from the group consisting of halo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, azido, C 1 -C 4 azidoalkyl, aryl, alkylaryl, haloaryl, haloalkylaryl, and combinations thereof; and R is selected from the group consisting of nitrile, acetonitrile, ethylnitrile, propylnitrile, carboxamide, amidine, tetrazole, oxime, hydrazone, acetamidine, aminoacetamide, guanidine, and urea. Also provided are methods of using the compounds for the treatment and prevention of cancer in humans.
1. A compound of formula I
wherein
X is selected from the group consisting of alkyl and haloalkyl;
Ar is selected from the group consisting of biphenyl, naphthyl, anthryl, phenanthrenyl, and fluorenyl; wherein Ar is optionally substituted with one or more substituents at any suitable position;
R is selected from the group consisting of —CH 2 CN, —CH 2 CH 2 CN, —CH 2 CH 2 CH 2 CN,
or pharmaceutically acceptable salts thereof.
2. The compound of claim 1 wherein X is C 1 to C 4 haloalkyl.
3. The compound of claim 2 wherein X is CF 3 .
4. The compound of claim 1 , wherein Ar is substituted at any substitutable position with one or more radicals selected from the group consisting of halo, C 1 -C 4 alkyl, C 1 -C 4 haloallyl, azido, C 1 -C 4 azidoalkyl, aryl, alkylaryl, haloaryl, haloalkylaryl, and combinations thereof.
5. The compound of claim 1 wherein Ar is selected from the group consisting of 2-naphthyl, 4-biphenyl, 9-anthryl, 2-fluorenyl, 4-azidophenyl, 4-azidomethylphenyl, 4-(2-azidoethyl)phenyl, 4-(3-azidopropyl)phenyl, 4-(4-azidobutyl)phenyl, 4-(4-azidophenyl)phenyl, 4-(4-azidomethylphenyl)phenyl, 4-methylphenyl, 4-ethylphenyl, 4-propylphenyl, 4-butylphenyl, 4-(2-bromoethyl)phenyl, 4-(3-bromopropyl)phenyl, 4-(4-bromobutyl)phenyl, 4-(trifluoromethyl)phenyl, 4-(4-methylphenyl)phenyl, 4-(4-bromomethylphenyl)phenyl, 4-(4-butylphenyl)phenyl, 4-(4-tert-butylphenyl)phenyl, 2-chlorophenyl, 4-chlorophenyl, 2,4-dichlorophenyl, 3,4-dichlorophenyl, 2,5-dichlorophenyl, 2,4-dimethylphenyl, 2,5-dimethylphenyl, 3,4-dimethylphenyl, 3,5-dimethylphenyl, 4-(4-chlorophenyl)phenyl, 4-(3,5-dichlorophenyl)phenyl, 4-(2,3-dichlorophenyl)phenyl, 4-(3,5-dimethylphenyl)phenyl, 4-(2,4,5-trichlorophenyl)phenyl, 4-(4-trifluoromethylphenyl)phenyl, 2-phenanthrenyl, 3-indolyl, 2-pyrrolyl, 4-(benzyl)phenyl. 4-t-butylphenyl, 9H-fluoren-2-yl, and 9-phenyanthrenyl.
6. The compound of claim 5 wherein Ar is 2-phenanthrenyl.
7. The compound of claim 1 wherein R is selected from aminoacetamide and guanidine.
8. The compound of claim 1 wherein X is CF 3 , Ar is 2-phenanthrenyl, and R is selected from aminoacetamide and guanidine.
9. A compound of formula II
wherein
X is selected from the group consisting of alkyl and haloalkyl;
R is selected from the group consisting of —CN, —CH 2 CN, —CH 2 CH 2 CN, —CH 2 CH 2 CH 2 CN,
or pharmaceutically acceptable salts thereof.
10. The compound of claim 9 wherein X is C 1 to C 4 haloalkyl.
11. The compound of claim 10 wherein X is CF 3 .
12. The compound of claim 9 wherein R is selected from aminoacetamide and guanidine or a pharmaceutically acceptable salt thereof.